Peptide Research · 5 min read

Tesamorelin: A GHRH Analog in Neuroendocrine Research

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog comprising the full 44-amino acid human GHRH sequence bearing a trans-3-hexenoic acid modification at the N-terminus. This structural alteration was engineered to improve metabolic stability and prolong biological activity relative to the native hormone. Tesamorelin exerts its effects by engaging the GHRH receptor on somatotroph cells of the anterior pituitary, thereby promoting endogenous growth hormone (GH) production and secretion.

Upon binding the GHRH receptor (GHRH-R) -- a G protein-coupled receptor on pituitary somatotrophs -- Tesamorelin triggers adenylate cyclase activation. The resulting rise in intracellular cyclic AMP (cAMP) engages protein kinase A (PKA), which in turn stimulates transcription of the GH gene and promotes hormone release into the circulation.

Clinical research has characterized the effects of Tesamorelin on the dynamics of growth hormone release. Investigators reported dose-dependent elevations in circulating GH and IGF-1 concentrations in study participants. A key observation is that the pulsatile GH secretion pattern remained intact, a feature that differentiates Tesamorelin from direct exogenous GH administration, which suppresses the body's own GH output.

Each MyPeptide reference page is organized around product identity, documentation, and research context rather than medical claims, dosing instructions, or personal-use outcomes.

Use the related links on this page to move between the catalog, COA records, policy pages, and supporting research guides while staying within the research-use-only scope.

Batch documentation, product identity, and compliance context are kept close together so qualified purchasers can review the material before continuing through the storefront.